Compare · BGLC vs LH
BGLC vs LH
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH is the larger of the two at $30.08B, about 12565.5x BGLC ($2.4M).
- LH has been more active in the news (11 items in the past 4 weeks vs 1 for BGLC).
- LH has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- Labcorp Holdings Inc.
- Price
- -
- -
- Market cap
- $2.4M
- $30.08B
- 1M return
- -
- +14.05%
- 1Y return
- -
- +41.93%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 11
- Recent ratings
- 0
- 25
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest BGLC
- BioNexus Launches New Corporate Website with Expanded Business and Investor Resources
- SEC Form 8-K filed by BioNexus Gene Lab Corp
- RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
- Chief Executive Officer Tan Lee Su-Leng was granted 338,709 shares (SEC Form 4)
- Director Yap Chee Keong was granted 32,258 shares (SEC Form 4)
- Director Bin Abdul Hamid Muhammad Azrul was granted 32,258 shares (SEC Form 4)
- Chief Financial Officer Chong Set Fui was granted 96,774 shares (SEC Form 4)
- Director Low Jook Yuen was granted 16,129 shares, increasing direct ownership by 1,279% to 17,390 units (SEC Form 4)
- SEC Form 10-Q filed by BioNexus Gene Lab Corp
- New insider Fidelion Diagnostics Pte. Ltd. claimed ownership of 392,329 shares (SEC Form 3)
Latest LH
- EVP, Pres of BLS, CMO & CSO Caveney Brian J sold $744,080 worth of shares (2,000 units at $372.04), decreasing direct ownership by 5% to 34,562 units (SEC Form 4)
- EVP and President, Diagnostics Vaughn Bryan T sold $108,232 worth of shares (306 units at $353.70) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 6,845 units (SEC Form 4)
- Labcorp Holdings Inc. upgraded by HSBC Securities with a new price target
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Speak at the UBS Global Healthcare Conference
- Director Parham Richelle P sold $389,395 worth of shares (1,078 units at $361.22), decreasing direct ownership by 32% to 2,288 units (SEC Form 4)
- EVP, CIO & CTO Oyegunwa Akinbolade converted options into 370 shares and covered exercise/tax liability with 118 shares, increasing direct ownership by 5% to 5,316 units (SEC Form 4) to satisfy tax liability
- EVP and President, Diagnostics Vaughn Bryan T converted options into 500 shares and covered exercise/tax liability with 194 shares, increasing direct ownership by 4% to 7,151 units (SEC Form 4) to cover taxes
- SEC Form 10-Q filed by Labcorp Holdings Inc.
- SEC Form 8-K filed by Labcorp Holdings Inc.